Medarex Inc.

E. R. Squibb Sons, Inc.

Northwest Biotherapeutics, Inc.

Northwest Hospital

Ala Wai Pharma, Inc.

Cytochem, Inc.

Pacific Northwest Research Foundation

Pacific Northwest Cancer Foundation

Gerald P. Murphy Cancer Foundation

Pacific Northwest Research

Eric H Holmes

Gerald P Murphy

Alton L Boynton

William T Tino

Josephine M Cardarelli

Peter Brams

Alison Witte

Cynthia A Vistica

Anne L Sherwood

Michael Hite

Thomas G Greene

Robert J Barren, Iii

The present disclosure provides isolated monoclonal antibodies, particularly human monoclonal antibodies that specifically bind to Fucosyl-GM1 with high affinity. Nucleic acid molecules encoding the antibodies of this disclosure, expression vectors, host cells and methods for expressing the antibodies of this disclosure are also provided. Immunoconjugates, bispecific molecules and pharmaceutical compositions comprising the antibodies of this disclosure are also provided. This disclosure also provides methods for detecting Fucosyl-GM1, as well as methods for treating various diseases, including cancer, using anti-Fucosyl-GM1 antibodies.

Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1 antibodies

A composition is described having improved oral permeability of polar agents such as neuraminidase inhibitors. The composition includes one or more polar agents and one or more permeability enhancers such that the composition increases the amount of the polar agent capable of being transported across a Caco-2 cell membrane by at least 150% relative to the amount capable of being transported across the Caco-2 Cell membrane in the absence of the permeability enhancer. Oral dosage forms including the composition, and methods of treating or preventing influenza infection are also provided.

Formulations for enhanced bioavailability of orally administered polar agents

Human monoclonal antibodies to Fucosyl-GM1 and methods for using anti-Fucosyl-GM1 antibodies

Human monoclonal antibodies to fucosyl-GM1 and methods for using anti-fucosyl-GM1

The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In particular, thirty-five monoclonal antibodies reactive with PSMA expressed on the cell surface are exemplified. Additionally, the present invention relates to a novel protein variant (PSM') of PSMA detected by a number of the antibodies of the invention. The hydrolase activity of PSMA and PSM&#x2032; allows the use of an immunoenzymatic assay for their detection.

Monoclonal antibody specific for the extracellular domain of prostate specific membrane antigen

Monoclonal antibodies specific for the extracellular domain of prostate-specific membrane antigen

The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In. particular, thirty-five monoclonal antibodies reactive with PSMA expressed on the cell surface are exemplified. Additionally, the present invention relates to a novel protein variant (PSM') of PSMA detected by a number of the antibodies of the invention. The hydrolase activity of PSMA and PSM&#x2032; allows the use of an immunoenzymatic assay for their detection.

The present invention relates to monoclonal antibodies that bind to the extracellular domain of prostate-specific membrane antigen (PSMA), hybridoma cell lines producing the antibodies, and methods of using such antibodies for diagnosis and treatment of cancer. In particular, thirty-five monoclonal antibodies reactive with PSMA expressed on the cell surface are exemplified. Additionally, the present invention relates to a novel protein variant (PSM') of the PSMA detected by a number of the antibodies of the invention. The hydrolase activity of PSMA and PSM&#x2032; allows the use of an immunoenzymatic assay for their detection.

A rat ganglioside GM-specific &#x3b1;1&#x2192;2fucosyltransferase is disclosed. Nucleotide sequences of a rat ganglioside GM-specific &#x3b1;1&#x2192;2fucosyltransferase, amino acid sequences of its encoded protein (including peptide or polypeptide), and derivatives thereof are described. Also described are fragments (and derivatives and analogs thereof) which comprise a domain of rat ganglioside GM-specific &#x3b1;1&#x2192;2fucosyltransferase with catalytic activity. Methods of production of rat ganglioside GM-specific &#x3b1;1&#x2192;2fucosyltransferase and derivatives and analogs thereof (e.g. by recombinant means) are provided. Methods of inhibiting the function of rat ganglioside GM-specific &#x3b1;1&#x2192;2fucosyltransferase (e.g. by means of antisense RNA) are provided. Methods of commercial scale use of the rat ganglioside GM-specific &#x3b1;1&#x2192;2fucosyltransferase in the production of fucosyl-saccharide compositions are described. Applications of these compositions, e.g. as additives for human nutritive compositions or immunotherapeutics for cancer, are disclosed.

Nucleic acids and proteins of a rat ganglioside GM1-specific &#x3b1;1-2fucosyltransferase and uses thereof

The present invention relates to methods and materials for the detection and quantitation 8-OH-Ade in biological specimens. Specifically, the present invention is directed to a group of highly specific monoclonal antibodies reactive with the modified nucleoside structure 8-OH-Ade, and to various immunoassays for 8-OH-Ade utilizing these monoclonal antibodies. The monoclonal antibodies of the present invention may be used in assays for diagnosing or monitoring the progression of certain types of cancer, in addition to a variety of other diseases associated with mutagenesis resulting from oxidative damage of DNA. Assays utilizing the monoclonal antibodies of the present invention may also be used to analyze or monitor toxicant exposure, such as from environmental sources. The monoclonal antibodies of the present invention were prepared with the immunogen 8-OH-adenosine coupled to keyhole limpet hemocyanin (KLH), not to 8-OH-Ade directly. It is believed that the monoclonal antibodies bind with the base portion of the structure (8-OH-Ade) and not the carbohydrate (ribose) or protein linkage region of the conjugate, because, as demonstrated, conjugates bound to nucleosides other than 8-OH-adenosine were unreactive with these antibodies. Therefore, the antibodies of the present invention can be used to detect and quantitate (by the use of a standard curve) the presence of 8-OH-Ade in biological specimens of DNA. Procedures for such an assay include immobilizing the DNA, denaturing it to disrupt the base-pairing scheme exposing the free base structures, and quantitating the amount of 8-OH-Ade present per amount of DAN in a quantitative immunoassay.

Detection and quantitation of 8-OH-adenine using monoclonal antibodies

A rat ganglioside GM -specific &agr;1&rarr;2fucosyltransferase is disclosed. Nucleotide sequences of a rat ganglioside GM -specific &agr;1&rarr;2fucosyltransferase, amino acid sequences of its encoded protein (including peptide or polypeptide), and derivatives thereof are described. Also described are fragments (and derivatives and analogs thereof) which comprise a domain of rat ganglioside GM -specific &agr;1&rarr;2fucosyltransferase with catalytic activity. Methods of production of rat ganglioside GM -specific &agr;1&rarr;2fucosyltransferase and derivatives and analogs thereof (e.g. by recombinant means) are provided. Methods of inhibiting the function of rat ganglioside GM -specific &agr;1&rarr;2fucosyltransferase (e.g. by means of antisense RNA) are provided. Methods of commercial scale use of the rat ganglioside GM -specific &agr;1&rarr;2fucosyltransferase in the production of fucosyl-saccharide compositions are described. Applications of these compositions, e.g. as additives for human nutritive compositions or immunotherapeutics for cancer, are disclosed.

Nucleic acids and proteins of a rat ganglioside GM1-specific &agr;1&rarr;2 fucosyltransferase and uses thereof

The present invention is directed to methods of detecting prostate cancer in a sample of a body fluid with prostate cell marker-specific and epithelial cell marker-specific antibodies as well as to kits comprising such antibodies for use in the detection of prostate cancer. The present invention is also directed to methods of detecting prostate cancer in a sample of a body fluid with prostate cell marker-specific and tumor associated marker-specific antibodies as well as to kits comprising such antibodies for use in the detection of prostate cancer.

Non-invasive method to detect prostate cancer

A rat ganglioside GM,-specific &agr;1&rarr;2fucosyltransferase is disclosed. Nucleotide sequences of a rat ganglioside GM,-specific &agr;1&rarr;2fucosyltransferase, amino acid sequences of its encoded protein (including peptide or polypeptide), and derivatives thereof are described. Also described are fragments (and derivatives and analogs thereof) which comprise a domain of rat ganglioside GM,-specific &agr;1&rarr;2fucosyltransferase with catalytic activity. Methods of production of rat ganglioside GM,-specific &agr;1&rarr;2fucosyltransferase and derivatives and analogs thereof (e.g. by recombinant means) are provided. Methods of inhibiting the function of rat ganglioside GM,-specific &agr;1&rarr;2fucosyltransferase (e.g. by means of antisense RNA) are provided. Methods of commercial scale use of the rat ganglioside GM,-specific &agr;1&rarr;2fucosyltransferase in the production of fucosyl-saccharide compositions are described. Applications of these compositions, e.g. as additives for human nutritive compositions or immunotherapeutics for cancer, are disclosed.

Growing community of inventors

Bothell, WA, United States of America

Eric H Holmes